23 May 2013
Keywords: pfizer, fablyn, gets, nod, chmp, global, drug
Article | 12 January 2009
Global drug giant Pfizer's drug Fablyn (lasofoxifene tartrate) has been recommended for approval for osteoporosis in women with increased risk
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
12 January 2009
22 May 2013
© 2013 thepharmaletter.com